Cost-Effectiveness of a Care Program for HIV/AIDS Patients Affiliated with a Health Insurer in Colombia, Comparing Three Health Care Providers Nationwide
In Colombia, HIV and AIDS constitute one of the major diseases of high cost to the health system, making necessary health risk management of patients with this disease through comprehensive health care programs with their respective evaluation of results. To evaluate the relative cost-effectiveness...
Gespeichert in:
| Veröffentlicht in: | Value in health regional issues 2016-12, Vol.11, p.1-8 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8 |
|---|---|
| container_issue | |
| container_start_page | 1 |
| container_title | Value in health regional issues |
| container_volume | 11 |
| creator | Guarín Téllez, Natalia Elizabeth Moreno Calderón, Jairo Alexander Muñoz-Galindo, Ivan Mauricio Augusto Díaz Rojas, Jorge Arévalo Roa, Helbert Orlando |
| description | In Colombia, HIV and AIDS constitute one of the major diseases of high cost to the health system, making necessary health risk management of patients with this disease through comprehensive health care programs with their respective evaluation of results.
To evaluate the relative cost-effectiveness of a care program for patients with HIV/AIDS affiliated to a health insurer in Colombia, comparing their results in three Health care provider (HCP).
The study population corresponded to a cohort of patients older than 18 years with HIV/AIDS and affiliated to a health insurer in Colombia during 2011 and 2012. A cost-effectiveness and cost-utility analysis of a health care program for this population was performed on the basis of a Markov model, in which quality-adjusted life-years (QALYs) and life-years gained were assessed. This analysis was conducted from the insurer perspective. The time horizon was life expectancy. A discount rate of 3% was applied.
Drugs accounted for 80.54% of care costs. The average annual cost of patients in health state 5 was 3 times higher than that of patients in state 1. HCP A compared with HCP B generated an additional 1.53 QALYs, with a rate of incremental cost-effectiveness of $2400 per QALY gained. HCP C showed a dominated behavior. The variables that most influence the uncertainty were the cost of HCP A in health state 5 (55.52%) and the cost of HCP B in state 3 (27.51%).
HCP A is a very cost-effective option considering a threshold of 1 time the per-capita gross domestic product. |
| doi_str_mv | 10.1016/j.vhri.2015.11.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1852692920</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2212109915000990</els_id><sourcerecordid>1799552629</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3431-18e31a2062c5b261ddaed4940596e228cea1ef3edc02ae31682c62ad165b71c33</originalsourceid><addsrcrecordid>eNp9kUFv0zAYhiMEYtPYH-CALHHhQDJ_X5o0lrhUYaOVJpjE4Gq59ufVVRIXO-nET-HfzlVXDhzwxZ-l531t-cmyt8AL4FBfbYv9JrgCOVQFQME5vMjOEQFzAI4vTzMX4iy7jHHL05rPeNnw19kZzkVTgyjPsz-tj2N-bS3p0e1poBiZt0yxVgVid8E_BNUz6wNbrn5eLVafv7M7NToaxsgW1rrOqZEMe3TjJoWWpLo0rIY4BQrMDaz1ne_XTn1MU79TwQ0P7H4TiE7s6Z69MxQi-5rK_fCYDm-yV1Z1kS6f94vsx831fbvMb799WbWL21yXsxJyaKgEhbxGXa2xBmMUmZmY8UrUhNhoUkC2JKM5qoTWDeoalYG6Ws9Bl-VF9uHYuwv-10RxlL2LmrpODeSnKKGpsBYokCf0_T_o1k9hSK-TMBeiSiCKROGR0sHHGMjKXXC9Cr8lcHlwJ7fy4E4e3EkAmdyl0Lvn6mndk_kbOZlKwKcjQOkv9o6CjDpp0GRcSO6k8e5__U9Dzqmx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1799552629</pqid></control><display><type>article</type><title>Cost-Effectiveness of a Care Program for HIV/AIDS Patients Affiliated with a Health Insurer in Colombia, Comparing Three Health Care Providers Nationwide</title><source>MEDLINE</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Guarín Téllez, Natalia Elizabeth ; Moreno Calderón, Jairo Alexander ; Muñoz-Galindo, Ivan Mauricio ; Augusto Díaz Rojas, Jorge ; Arévalo Roa, Helbert Orlando</creator><creatorcontrib>Guarín Téllez, Natalia Elizabeth ; Moreno Calderón, Jairo Alexander ; Muñoz-Galindo, Ivan Mauricio ; Augusto Díaz Rojas, Jorge ; Arévalo Roa, Helbert Orlando</creatorcontrib><description>In Colombia, HIV and AIDS constitute one of the major diseases of high cost to the health system, making necessary health risk management of patients with this disease through comprehensive health care programs with their respective evaluation of results.
To evaluate the relative cost-effectiveness of a care program for patients with HIV/AIDS affiliated to a health insurer in Colombia, comparing their results in three Health care provider (HCP).
The study population corresponded to a cohort of patients older than 18 years with HIV/AIDS and affiliated to a health insurer in Colombia during 2011 and 2012. A cost-effectiveness and cost-utility analysis of a health care program for this population was performed on the basis of a Markov model, in which quality-adjusted life-years (QALYs) and life-years gained were assessed. This analysis was conducted from the insurer perspective. The time horizon was life expectancy. A discount rate of 3% was applied.
Drugs accounted for 80.54% of care costs. The average annual cost of patients in health state 5 was 3 times higher than that of patients in state 1. HCP A compared with HCP B generated an additional 1.53 QALYs, with a rate of incremental cost-effectiveness of $2400 per QALY gained. HCP C showed a dominated behavior. The variables that most influence the uncertainty were the cost of HCP A in health state 5 (55.52%) and the cost of HCP B in state 3 (27.51%).
HCP A is a very cost-effective option considering a threshold of 1 time the per-capita gross domestic product.</description><identifier>ISSN: 2212-1099</identifier><identifier>EISSN: 2212-1102</identifier><identifier>DOI: 10.1016/j.vhri.2015.11.001</identifier><identifier>PMID: 27986193</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acquired immune deficiency syndrome ; Acquired Immunodeficiency Syndrome - economics ; Acquired Immunodeficiency Syndrome - therapy ; AIDS ; Colombia ; Cost analysis ; Cost-Benefit Analysis ; GDP ; Gross Domestic Product ; Health care ; Health Care Costs ; Health care expenditures ; Health Personnel ; Health services ; HIV ; Human immunodeficiency virus ; Humans ; impact assessment health ; Insurance Carriers ; Life expectancy ; Medical personnel ; Patients ; program evaluation ; Quality adjusted life years ; Risk management ; Uncertainty ; Utility analysis</subject><ispartof>Value in health regional issues, 2016-12, Vol.11, p.1-8</ispartof><rights>2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR)</rights><rights>Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3431-18e31a2062c5b261ddaed4940596e228cea1ef3edc02ae31682c62ad165b71c33</citedby><cites>FETCH-LOGICAL-c3431-18e31a2062c5b261ddaed4940596e228cea1ef3edc02ae31682c62ad165b71c33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,30999</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27986193$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guarín Téllez, Natalia Elizabeth</creatorcontrib><creatorcontrib>Moreno Calderón, Jairo Alexander</creatorcontrib><creatorcontrib>Muñoz-Galindo, Ivan Mauricio</creatorcontrib><creatorcontrib>Augusto Díaz Rojas, Jorge</creatorcontrib><creatorcontrib>Arévalo Roa, Helbert Orlando</creatorcontrib><title>Cost-Effectiveness of a Care Program for HIV/AIDS Patients Affiliated with a Health Insurer in Colombia, Comparing Three Health Care Providers Nationwide</title><title>Value in health regional issues</title><addtitle>Value Health Reg Issues</addtitle><description>In Colombia, HIV and AIDS constitute one of the major diseases of high cost to the health system, making necessary health risk management of patients with this disease through comprehensive health care programs with their respective evaluation of results.
To evaluate the relative cost-effectiveness of a care program for patients with HIV/AIDS affiliated to a health insurer in Colombia, comparing their results in three Health care provider (HCP).
The study population corresponded to a cohort of patients older than 18 years with HIV/AIDS and affiliated to a health insurer in Colombia during 2011 and 2012. A cost-effectiveness and cost-utility analysis of a health care program for this population was performed on the basis of a Markov model, in which quality-adjusted life-years (QALYs) and life-years gained were assessed. This analysis was conducted from the insurer perspective. The time horizon was life expectancy. A discount rate of 3% was applied.
Drugs accounted for 80.54% of care costs. The average annual cost of patients in health state 5 was 3 times higher than that of patients in state 1. HCP A compared with HCP B generated an additional 1.53 QALYs, with a rate of incremental cost-effectiveness of $2400 per QALY gained. HCP C showed a dominated behavior. The variables that most influence the uncertainty were the cost of HCP A in health state 5 (55.52%) and the cost of HCP B in state 3 (27.51%).
HCP A is a very cost-effective option considering a threshold of 1 time the per-capita gross domestic product.</description><subject>Acquired immune deficiency syndrome</subject><subject>Acquired Immunodeficiency Syndrome - economics</subject><subject>Acquired Immunodeficiency Syndrome - therapy</subject><subject>AIDS</subject><subject>Colombia</subject><subject>Cost analysis</subject><subject>Cost-Benefit Analysis</subject><subject>GDP</subject><subject>Gross Domestic Product</subject><subject>Health care</subject><subject>Health Care Costs</subject><subject>Health care expenditures</subject><subject>Health Personnel</subject><subject>Health services</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>impact assessment health</subject><subject>Insurance Carriers</subject><subject>Life expectancy</subject><subject>Medical personnel</subject><subject>Patients</subject><subject>program evaluation</subject><subject>Quality adjusted life years</subject><subject>Risk management</subject><subject>Uncertainty</subject><subject>Utility analysis</subject><issn>2212-1099</issn><issn>2212-1102</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNp9kUFv0zAYhiMEYtPYH-CALHHhQDJ_X5o0lrhUYaOVJpjE4Gq59ufVVRIXO-nET-HfzlVXDhzwxZ-l531t-cmyt8AL4FBfbYv9JrgCOVQFQME5vMjOEQFzAI4vTzMX4iy7jHHL05rPeNnw19kZzkVTgyjPsz-tj2N-bS3p0e1poBiZt0yxVgVid8E_BNUz6wNbrn5eLVafv7M7NToaxsgW1rrOqZEMe3TjJoWWpLo0rIY4BQrMDaz1ne_XTn1MU79TwQ0P7H4TiE7s6Z69MxQi-5rK_fCYDm-yV1Z1kS6f94vsx831fbvMb799WbWL21yXsxJyaKgEhbxGXa2xBmMUmZmY8UrUhNhoUkC2JKM5qoTWDeoalYG6Ws9Bl-VF9uHYuwv-10RxlL2LmrpODeSnKKGpsBYokCf0_T_o1k9hSK-TMBeiSiCKROGR0sHHGMjKXXC9Cr8lcHlwJ7fy4E4e3EkAmdyl0Lvn6mndk_kbOZlKwKcjQOkv9o6CjDpp0GRcSO6k8e5__U9Dzqmx</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Guarín Téllez, Natalia Elizabeth</creator><creator>Moreno Calderón, Jairo Alexander</creator><creator>Muñoz-Galindo, Ivan Mauricio</creator><creator>Augusto Díaz Rojas, Jorge</creator><creator>Arévalo Roa, Helbert Orlando</creator><general>Elsevier Inc</general><general>Elsevier Science Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7X8</scope></search><sort><creationdate>20161201</creationdate><title>Cost-Effectiveness of a Care Program for HIV/AIDS Patients Affiliated with a Health Insurer in Colombia, Comparing Three Health Care Providers Nationwide</title><author>Guarín Téllez, Natalia Elizabeth ; Moreno Calderón, Jairo Alexander ; Muñoz-Galindo, Ivan Mauricio ; Augusto Díaz Rojas, Jorge ; Arévalo Roa, Helbert Orlando</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3431-18e31a2062c5b261ddaed4940596e228cea1ef3edc02ae31682c62ad165b71c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Acquired Immunodeficiency Syndrome - economics</topic><topic>Acquired Immunodeficiency Syndrome - therapy</topic><topic>AIDS</topic><topic>Colombia</topic><topic>Cost analysis</topic><topic>Cost-Benefit Analysis</topic><topic>GDP</topic><topic>Gross Domestic Product</topic><topic>Health care</topic><topic>Health Care Costs</topic><topic>Health care expenditures</topic><topic>Health Personnel</topic><topic>Health services</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>impact assessment health</topic><topic>Insurance Carriers</topic><topic>Life expectancy</topic><topic>Medical personnel</topic><topic>Patients</topic><topic>program evaluation</topic><topic>Quality adjusted life years</topic><topic>Risk management</topic><topic>Uncertainty</topic><topic>Utility analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guarín Téllez, Natalia Elizabeth</creatorcontrib><creatorcontrib>Moreno Calderón, Jairo Alexander</creatorcontrib><creatorcontrib>Muñoz-Galindo, Ivan Mauricio</creatorcontrib><creatorcontrib>Augusto Díaz Rojas, Jorge</creatorcontrib><creatorcontrib>Arévalo Roa, Helbert Orlando</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>MEDLINE - Academic</collection><jtitle>Value in health regional issues</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guarín Téllez, Natalia Elizabeth</au><au>Moreno Calderón, Jairo Alexander</au><au>Muñoz-Galindo, Ivan Mauricio</au><au>Augusto Díaz Rojas, Jorge</au><au>Arévalo Roa, Helbert Orlando</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-Effectiveness of a Care Program for HIV/AIDS Patients Affiliated with a Health Insurer in Colombia, Comparing Three Health Care Providers Nationwide</atitle><jtitle>Value in health regional issues</jtitle><addtitle>Value Health Reg Issues</addtitle><date>2016-12-01</date><risdate>2016</risdate><volume>11</volume><spage>1</spage><epage>8</epage><pages>1-8</pages><issn>2212-1099</issn><eissn>2212-1102</eissn><abstract>In Colombia, HIV and AIDS constitute one of the major diseases of high cost to the health system, making necessary health risk management of patients with this disease through comprehensive health care programs with their respective evaluation of results.
To evaluate the relative cost-effectiveness of a care program for patients with HIV/AIDS affiliated to a health insurer in Colombia, comparing their results in three Health care provider (HCP).
The study population corresponded to a cohort of patients older than 18 years with HIV/AIDS and affiliated to a health insurer in Colombia during 2011 and 2012. A cost-effectiveness and cost-utility analysis of a health care program for this population was performed on the basis of a Markov model, in which quality-adjusted life-years (QALYs) and life-years gained were assessed. This analysis was conducted from the insurer perspective. The time horizon was life expectancy. A discount rate of 3% was applied.
Drugs accounted for 80.54% of care costs. The average annual cost of patients in health state 5 was 3 times higher than that of patients in state 1. HCP A compared with HCP B generated an additional 1.53 QALYs, with a rate of incremental cost-effectiveness of $2400 per QALY gained. HCP C showed a dominated behavior. The variables that most influence the uncertainty were the cost of HCP A in health state 5 (55.52%) and the cost of HCP B in state 3 (27.51%).
HCP A is a very cost-effective option considering a threshold of 1 time the per-capita gross domestic product.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27986193</pmid><doi>10.1016/j.vhri.2015.11.001</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2212-1099 |
| ispartof | Value in health regional issues, 2016-12, Vol.11, p.1-8 |
| issn | 2212-1099 2212-1102 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1852692920 |
| source | MEDLINE; Applied Social Sciences Index & Abstracts (ASSIA); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Acquired immune deficiency syndrome Acquired Immunodeficiency Syndrome - economics Acquired Immunodeficiency Syndrome - therapy AIDS Colombia Cost analysis Cost-Benefit Analysis GDP Gross Domestic Product Health care Health Care Costs Health care expenditures Health Personnel Health services HIV Human immunodeficiency virus Humans impact assessment health Insurance Carriers Life expectancy Medical personnel Patients program evaluation Quality adjusted life years Risk management Uncertainty Utility analysis |
| title | Cost-Effectiveness of a Care Program for HIV/AIDS Patients Affiliated with a Health Insurer in Colombia, Comparing Three Health Care Providers Nationwide |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T06%3A20%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-Effectiveness%20of%20a%20Care%20Program%20for%20HIV/AIDS%20Patients%20Affiliated%20with%20a%20Health%20Insurer%20in%20Colombia,%20Comparing%20Three%20Health%20Care%20Providers%20Nationwide&rft.jtitle=Value%20in%20health%20regional%20issues&rft.au=Guar%C3%ADn%20T%C3%A9llez,%20Natalia%20Elizabeth&rft.date=2016-12-01&rft.volume=11&rft.spage=1&rft.epage=8&rft.pages=1-8&rft.issn=2212-1099&rft.eissn=2212-1102&rft_id=info:doi/10.1016/j.vhri.2015.11.001&rft_dat=%3Cproquest_cross%3E1799552629%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1799552629&rft_id=info:pmid/27986193&rft_els_id=S2212109915000990&rfr_iscdi=true |